73 results about "Neo angiogenesis" patented technology

The invention relates to a peptide for high performance inhibition of angiogenesis and method for preparing same and use, wherein high performance blood vessel production inhibiting agent RGD-ED with integration compatibility is designed, the inhibiting agent comprises polypeptide polypeptide-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-praline, its one or two ends are connected with polypeptides containing arginine-glycine-aspartic acid sequence. The RGD-ED provided by the invention can be synthesized. The invention also discloses the expression of one RGD-ED in bacillus coli through gene engineering method, wherein the RGD-ED is prepared through the steps of inclusion body protein segregation, dissolution and renaturation, and ion-exchange chromatography segregation and purification.

The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and / or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.

The invention relates to a high-performance angiogenesis inhibitor and a production method, which belongs to the field of the biological engineering pharmaceutical technology or protein polypeptide drugs. The invention designs a high-performance angiogenesis inhibitor RGD-ED with integrin compatibility, the inhibitor contains angiogenesis inhibition polypeptide isoleucine-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-proline, and one or two ends of the inhibitor are respectively connected with polypeptides containing arginine-glycin-aspartate sequence. The RGD-ED of the invention can be synthesized. By the method of genetic engineering, the invention also expresses one of RGD-Eds in escherichia coli or other eukaryotic cells, and the RGD-ED is obtained by carrying out the separation, dissolution and renaturation of inclusion body protein and separation and purification by ion exchange chromatography. All the polypeptide sequences of the invention are modified by Polyethylene Glycol (PEG), heparin, dextran, polyvinylpyrrolidone (PVP), polyglycol-poly (amino acid) copolymer, palmitic acid, colominic acid and liposome, which includes liposome (REV), drying liposomal (DRV) and multivesicular liposome (Mvl). In vivo and in vitro experiments, the synthetic polypeptide sequence, product of genetic engineering and modified product of the invention can notably increase the effects of inhibiting the growth of endothelial cells, inhibiting angiogenesis and resisting tumor of the present angiogenesis inhibitors, and moreover, the high-performance angiogenesis inhibitor can be used as a drug curing solid tumors and rheumatoid arthritis.

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

The invention relates to the action of phthalimide derivatives of formula I and II in the preparation of medicament against angiogenesis, wherein the definitions of each substituent group are described in the specification.

The present invention relates to ophthalmic pharmaceutical compositions comprising Sorafenib, its derivatives or active metabolites, for the treatment and prevention of ocular neoangiogenic pathologies.

The invention discloses an angiogenesis inhibiting peptide, a hyaluronic acid modified compound thereof and a preparation method and application of the hyaluronic acid modified compound. The amino acid sequence of an ES-2-AF peptide is represented by SEQ ID NO.1 in a sequence table; and the hyaluronic acid modified compound of tge ES-2-AF peptide is formed by amino groups of the ES-2-AF peptide and carboxy groups on hyaluronic acid molecules through bonding of amido bonds, and the structural formula is HA-CO-NH-(ES-2-AF)n. Compared with an anti-flt1 peptide and an ES2 peptide, the ES-2-AF peptide has the advantage that the capacity of inhibiting angiogenesis is preserved and even enhanced. Compared with the ES-2-AF peptide, the hyaluronic acid modified compound has the advantages that the antiangiogenic activity and anti-tumor activity of the ES-2-AF peptide are preserved, the properties of antiangiogenesis and the like of macromolecule hyaluronic acid are integrated, and the hyaluronic acid modified compound has the characteristics of relatively high stability, relatively strong hydrophilcity and targeting property and the like, so that the hyaluronic acid modified compound has relatively good use effects and application values.

The invention is relative to novel means of systemic or mucosal vaccinial therapy against some cancers, viral infections and allergy which are provided by the invention under the form of a family of composite superimmunogenic compounds for bifunctional vaccinial use able to induce an immune response raised towards two distinct targets, respectively, the causal pathogenic antigenic structure, on the one hand, and locally produced factors responsible for a subsequent immunotoxic or neoangiogenic stroma disorder, on the other hand.

The invention discloses a compound which is shown as a formula (I) and used for inhibiting generation of tumour neovascularization as well as officinal salt or a configurational isomer thereof, wherein substituent groups R1, R2 and R3 are defined in the specification. The invention also discloses a preparation method of the compound in the formula (I), a pharmaceutical composition and an application of the compound as a microtubulin inhibitor in the aspect of inhibiting the tumour neovascularization, especially an application as an oral preparation.

The invention relates to a chicken germ yolk capsular vessel generating model, as living test model for detecting or selecting the drug which can affect novel vessel. The invention comprises that removing frame of 60h old germ to be put into a small beaker to cultivate for 12h, adding object drug into a silica gel ring on the yolk capsule, the contrast liquid and object liquid both contain glycerin or dimethyl sulfoxide as penetrant, taking off the silica gel ring after 12h, dynamically watching the effect of drug on the yolk capsular vessel. The function of drug on the vessel as restrain, simulate or non function can be judged according to the growth state of the yolk capsular vessel. Compared with traditional model, the invention is simple, visual, quick and accurate.

The present invention relates to the use of short interfering nucleic acid molecules (siNA, such as siRNA) that modulate the expression of VEGF-C and / or RhoA involved in neovascular angiogenesis. In the present invention, inhibition of VEGF-C and / or RhoA gene expression results in decreased expression of VEGF-A, which is required for the initiation and persistence of angiogenesis. Furthermore, the present invention also relates to the inhibition of RhoA expression levels and VEGF-C expression levels to gain the benefit of downregulating two different targets required for angiogenesis. The present invention describes compounds, compositions and methods for the inhibition of neovascularization. In certain embodiments, the present invention relates to methods for inhibiting neovascularization, and compounds for treating ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and other neovascular diseases , such as VEGF-C siRNA and RhoAsiRNA.

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

The invention provides application of polysaccharide sulphate to preparation of tumor treatment neovascularization inhibitors and vascular disrupting agents. Experiments prove that the neovascularization inhibiting rate, the maturation blood vessel disrupting rate and the concentration of the polysaccharide sulphate are in dosage relying relationship in a certain range, and the maturation blood vessel disrupting rate and the polysaccharide sulphate acting time are in dosage relying relationship. The application provided by the invention has the advantages that the effect of the polysaccharide sulphate in the aspects of tumor neovascularization inhibiting and tumor blood vessel generation disrupting can be proved, and the polysaccharide sulphate can be used for tumor blood vessel generation and other blood vessel generation disease treatment, and can also be used in aspects of tumor chemotherapy and / or auxiliary chemotherapy. Many diseases of people are relevant to the blood vessel generation, and the polysaccharide sulphate as the neovascularization inhibitors and vascular disrupting agents can be widely applied to the treatment of diseases of tumor and the like. The application provided by the invention has the advantages that the application range of the polysaccharide sulphate is widened, and the scientific basis is provided for the purpose development of the polysaccharide sulphate in the anti-tumor aspect and the like.

The present invention describes novel compounds of the formula:(Q)d-Ln-Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The invention relates to a peptide for high performance inhibition of angiogenesis and method for preparing same and use, wherein high performance blood vessel production inhibiting agent RGD-ED with integration compatibility is designed, the inhibiting agent comprises polypeptide polypeptide-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-praline, its one or two ends are connected with polypeptides containing arginine-glycine-aspartic acid sequence. The RGD-ED provided by the invention can be synthesized. The invention also discloses the expression of one RGD-ED in bacillus coli through gene engineering method, wherein the RGD-ED is prepared through the steps of inclusion body protein segregation, dissolution and renaturation, and ion-exchange chromatography segregation and purification.

The invention discloses a preparation method and application of a magnetic exosome-entrapped refractory wound dressing. The preparation method comprises the following steps of firstly, mixing a chitosan solution with a betasodium glycerophosphate solution to obtain a mixed solution I; then adding a hydroxyethyl cellulose solution into the mixed solution I to obtain a mixed solution II; co-incubating the human mesenchymal stem cells and the Fe3O4 superparamagnetic nanoparticles, extracting to obtain magnetic exosomes, and adding the magnetic exosomes into the mixed solution II to prepare the temperature-sensitive hydrogel dressing entrapping the magnetic exosomes. The hydrogel dressing prepared by the method has excellent temperature sensitivity, can be injected for administration, has theeffects of resisting bacteria, promoting angiogenesis and the like, and has a good application prospect in promotion of refractory wound repair.

The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and / or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immunodeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.

The invention belongs to the fields of pharmaceutical engineering and biotechnology, particularly relates to a prescription process for preparing a shikonin liposome and an effect of the shikonin liposome on resisting generation of new blood vessels. A human umbilical vein endothelial cell (HUVEC) strain is adopted in an anti-angiogenic test, and inhibition (MTT) on a proliferation effect thereof and inhibition (Transwell) on a migration effect thereof are measured. In addition, the invention also relates to shikonin cysts in liposomes, bright red fluorescent light can be observed under the excitation of green fluorescent light, and the shikonin cysts have important application values in the aspects of encapsulation rate measurement, in-vitro cellular localization, endocytosis mechanisms, in-vivo drug tracking and the like. After the shikonin liposomes act on the HUVEC or other tumor cells for a period of time, a confocal microscopy can be used for carrying out cellular fluorescent localization.

The invention discloses application of salted indianmulberry root polysaccharide in preparation of functional food with the effect of helping inhibit prostate cancer. Salted indianmulberry root polysaccharide is preferably prepared by the following method: processing indianmulberry root used as a raw material with salt, extracting with boiling water, removing protein, dialyzing and carrying out ethanol treatment. The indianmulberry root polysaccharide has the function of adjusting the tumor microenvironment. The salted indianmulberry root polysaccharide can adjust the tumor microenvironment through multiple ways such as inhabitation of tumor angiogenesis, inhabitation of immunity and inhabitation of fibroblast growth of the prostate cancer, so that the salted indianmulberry root polysaccharide has a good effect of helping inhibit prostate tumors.

The invention discloses application of ginsenoside Rg3 in combination with GP as an antitumor drug. A mouse Lewis lung cancer cell line (LLC) is selected and inoculated to the right armpit of a C57BL / 6N mouse, and the influence of ginsenoside Rg3 and Rg3 in combination with GP on Lewis lung cancer is observed; hematoxylin-eosin staining is performed on the liver, kidney, spleen and tumors, and pathological changes of ginsenoside Rg3 in combination with GP on the liver, kidney, spleen and tumors of mice with the Lewis lung cancer are detected; and tumor tissues are subjected to immunohistochemical staining, and the density of blood vessels in tumors and the expression of tumor platelet surface activation markers are detected. The conclusion is that the ginsenoside Rg3 in combination with GPcan enhance the effects of ginsenoside Rg3 of inhibiting the tumor growth of the mice with the Lewis lung cancer and inhibiting tumor angiogenesis, and the tumor inhibition effect of the ginsenosideRg3 is possibly and closely related to CD62P expression reduction; and the ginsenoside Rg3 in combination with GP can achieve the synergistic and toxicity-reducing effects.

The invention discloses application of codonopsis pilosula polysaccharides to the preparation of a functional food with the effect of helping to inhibit prostate cancer. Optimally, the codonopsis pilosula polysaccharides are prepared from codonopsis pilosula and by the procedures of extracting with boiled water, removing proteins, carrying out dialysis and carrying out ethanol treatment. The codonopsis pilosula polysaccharides have the effect of adjusting a tumor microenvironment through a plurality of manners of inhibiting tumor angiogenesis, carrying out immune activation, inhibiting fibroblast growth of prostate cancer and the like, so that the codonopsis pilosula polysaccharides have the good effect of helping to inhibit prostate cancer.

The invention provides methods and preparations for treating disorders of the eye and / or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compounds capable of causing nonenzymatic dissoultion of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure of formula (I).

The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.

The invention relates to a chicken germ yolk capsular vessel generating model, as living test model for detecting or selecting the drug which can affect novel vessel. The invention comprises that removing frame of 60h old germ to be put into a small beaker to cultivate for 12h, adding object drug into a silica gel ring on the yolk capsule, the contrast liquid and object liquid both contain glycerin or dimethyl sulfoxide as penetrant, taking off the silica gel ring after 12h, dynamically watching the effect of drug on the yolk capsular vessel. The function of drug on the vessel as restrain, simulate or non function can be judged according to the growth state of the yolk capsular vessel. Compared with traditional model, the invention is simple, visual, quick and accurate.

The invention relates to a cRGD-quaternized chitosan oligosaccharide modified ES2 peptide-methotrexate conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The CREM peptide conjugate can be prepared by controlling the conditions such as the supply quantity of the cRGD, the ES2 peptide and the MTX, the pH of a reaction system, the reaction time and the like. Compared with the ES2 peptide, the cRGD-quaternized chitosan oligosaccharide modified and methotrexate combined conjugate of the ES2 peptide keeps the anti-angiogenesis and anti-tumor activity of the ES2 peptide, integrates the tumor targeting property of cRGD and the anti-tumor activity of methotrexate and the like, has the characteristics of higher stability, hydrophilicity, targeting property and the like; therefore, the oligosaccharide has better use effect and application value.